ClinicalTrials.gg
RecruitingNCT07009158Updated Sep 15, 2026

Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD

A Phase 1/2 interventional study of Ketamine Infusion and Mindfulness-based cognitive therapy in Chronic Pain and Posttraumatic Stress Disorder (PTSD), sponsored by Dr. Yuliya Knyahnytska. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Dr. Yuliya Knyahnytska · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing ketamine in Chronic Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Ketamine · Chronic Pain.

Planned enrollment
20th of 32
30 · median 44
Started
2026
with 2 others
Phase 1/2
Only one
of the 32
Registered
30th of 32
by date
Lead sponsor
1 of 32
Dr. Yuliya Knyahnytska

Among the 32 studies testing ketamine in Chronic Pain, this one is the 20th largest by planned enrollment, is one of 3 that started in 2026, is the only one in phase 1/2, and was the 30th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

4 of the 32 studies testing ketamine in Chronic Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing ketamine in Chronic Pain, or all of them as a file.
02

Study summary

The goal of this pilot study is to evaluate the feasibility of conducting a clinical trial assessing if ketamine infusions combined to mindfulness therapy works better than psychotherapy alone to treat chronic pain and PTSD in adults living with both conditions. The objectives of the pilot study are to 1) assess the feasibility of the trial methods and 2) assess the feasibility and tolerability of ketamine treatment in combination with psychotherapy. The main questions the future full trial would aim to answer are:

  • Does the combination of ketamine infusion treatment and mindfulness therapy improve the quality of life in adults living with both chronic pain and PTSD more effectively than mindfulness therapy alone?"
  • Does the combination of ketamine infusion treatment and mindfulness therapy improve disability, and depressive, PTSD and pain symptoms in adults living with both chronic pain and PTSD more effectively than mindfulness therapy alone?"
  • Does implementing a brief ketamine infusion protocol safe and tolerable to treat chronic pain and PTSD?

Researchers will compare ketamine infusion treatment combined with mindfulness therapy to mindfulness therapy alone to see if the combined treatment works better to treat chronic pain and PTSD.

Participants will:

  • Attend 6 visits with a research team member to complete assessments and questionnaires.
  • Attend 4 ketamine treatment over 2 weeks, if allocated to the experimental group.
  • Attend 8 mindfulness therapy group sessions online (1 per week).
  • Log mindfulness exercises completed during the study period.
03

Conditions studied

  • Chronic Pain
  • Posttraumatic Stress Disorder (PTSD)

Keywords

  • Ketamine
  • Mindfulness-based Cognitive Therapy
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

i) A current diagnosis of PTSD (confirmed by the Mini International Neuropsychiatric Interview (66)) ii) Chronic pain (> 4/10 average pain reported for longer than 3 months (per (67)).

iii) 18-65 years of age. iv) Capacity to consent

Exclusion criteria

Exclusion Criteria:

i) Currently receiving or received ketamine or psychotherapy to treat PTSD in previous 8 weeks.

ii) Meeting criteria for substance abuse disorder within the past month or lifetime history of ketamine abuse.

iii) Concomitant unstable major medical or neurological conditions, or laboratory/imaging results as considered by the study treating physician to interfere with trial participation (e.g. poorly controlled blood pressure, >35).

iv) Pregnancy or the intention to become pregnant and breastfeeding during the study as confirmed by self-report. Participants must be willing to use a medically acceptable method of which include abstinence, hormonal (birth control pills, patch, hormone injections or implants), diaphragm with spermicide or cervical cap, IUD, condom used together with spermicide, surgical sterilization (hysterectomy or partner's vasectomy) and more than 2 years.

v) DSM-5 diagnosis of bipolar disorder, psychotic disorder, or a severe personality disorder which may interfere with the trial. Patients with lifelong diagnosis of Bipolar Disorder, Schizophrenia or Schizoaffective disorder will be excluded. Patients with primary Obsessive Compulsive Disorder, Substance Use Disorder (dependence and abuse), Seasonal Affective Disorder, or Generalized Anxiety Disorder at time of assessment will be excluded. Primary severe borderline personality disorder and any other personality disorders that potentially may interfere with treatment administration will also be excluded.

vi) Deemed to be high suicidal risk during the baseline assessment as per treating physician. Chronic persistent suicidality is not an exclusion.

vii) Use of medications that might interfere with ketamine efficacy such as benzodiazepines with a dose equivalent to lorazepam 2mg/day or higher, and anti-convulsant (except for pregabalin and gabapentin).

viii) Deemed not appropriate to engage in group psychotherapy. ix) Inability to communicate in spoken and written English fluently enough to complete the required study assessments or a non-correctable sensory impairment (i.e., cannot hear or see well enough to complete clinical assessments).

x) Cognitive or physical impairment severe enough to interfere with IV ketamine administration and the subject's ability to stay in the same place for a 2-hr monitoring supervision.

xi) Inability to secure a responsible adult to accompany them back home after ketamine sessions.

xii) Inability to take part in virtual care, no valid email address. xiii) Inability to safely secure IV access.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    KAP group

    The Ketamine-assisted psychotherapy (KAP) group will receive 4 ketamine infusion treatments and 8 sessions of mindfulness therapy.

    Drug: Ketamine Infusion · Behavioral: Mindfulness-based cognitive therapy

  • Active comparator
    MT group

    The mindfulness therapy (MT) group will receive only the psychotherapy treatment (8 sessions mindfulness therapy).

    Behavioral: Mindfulness-based cognitive therapy

Interventions

  • DrugKetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ketamine hydrochloride (DIN: 02246795, 02246796) will be administered over 40-min intravenous (IV) infusion twice per week on non-consecutive days for the first two weeks of study treatment (four treatment sessions in total). We will use a standard dose of 0.5mg/kg which has demonstrated efficacy in safety in individuals with PTSD.

  • BehavioralMindfulness-based cognitive therapy

    The Mindfulness-based cognitive therapy (MBCT) will be an 8-week group program adapted from a protocol developed to treat PTSD to include psychoeducation about chronic pain and mutual maintenance factors through which chronic pain and PTSD facilitate each other. The MBCT group will be delivered by trained professionals in weekly 2-hour sessions through Microsoft Teams. The 8-week program will include 1) mindfulness techniques; 2) psychoeducation regarding chronic pain, PTSD and stress responses; 3) psychoeducation on mutual maintenance factors that contribute to negative interactions between pain and PTSD symptoms, 4) promoting mindful awareness of these factors' impact on daily life and 5) feedback and supportive group discussion of exercises. Participants will be asked to complete daily mindfulness exercises between sessions to practice skills learned for a recommended minimum of 20 minutes per day.

06

What researchers measure

Primary outcomes

  1. Health-Related Quality of Life

    Measured using the Short-Form-12 Health Survey (SF-12v2)

    Time frame: Enrollment, 1 week pre-treatment, mid-treatment (1month), post-treatment (2months) and follow-up (3months)

Secondary outcomes

  1. Depressive symptoms

    Measured using the Montgomery-Asberg Depression Rating Scale (MADRS)

    Time frame: At enrollment, 1 week pre-treatment, mid-treatment (1 month), post-treatment (2 month), follow-up (3 months)

  2. Suicide risk

    Suicide risk will be measured using the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: At enrollment, 1 week pre-treatment, mid-treatment (1 month), post-treatment (2 month), follow-up (3 months)

  3. PTSD symptoms

    Measured using the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5).

    Time frame: At enrollment, 1 week pre-treatment, mid-treatment (1 month), post-treatment (2 month), follow-up (3 months)

  4. Pain Severity

    Pain Severity will be measured using the Brief Pain Inventory - Short Form (BPI)

    Time frame: At enrollment, 1 week pre-treatment, mid-treatment (1 month), post-treatment (2 month), follow-up (3 months)

  5. Pain Interference

    Pain Interference will be measured using the Brief Pain Inventory - Short Form (BPI)

    Time frame: At enrollment, 1 week pre-treatment, mid-treatment (1 month), post-treatment (2 month), follow-up (3 months)

  6. Disability

    Measured using the WHO Disability Assessment Schedule (WHODAS 2.0- 12 items)

    Time frame: At enrollment, 1 week pre-treatment, mid-treatment (1 month), post-treatment (2 month), follow-up (3 months)

  7. Adverse events

    Measured using a adverse events form.

    Time frame: From enrollment to 1 month after the end of the 8-week treatment period

Other outcomes

  1. Baseline Characteristics

    To describe the study population, the investigators will capture the following through the survey: age, sex, gender, duration of pain, locations of pain, current work status, military status, education, income, and ethnicity.

    Time frame: Enrollment

  2. Concomitant medication

    A list of medication currently used will be provided by the participants. Participants will be asked to talk the the research team before making any changes or start new medications during study period.

    Time frame: At enrollment and follow-up (3 months)

07

Study locations

1 of 1 sites recruiting
  • Providence Care Hospital / Kingston Health Sciences Centre Hotel Dieu Hospital site
    Kingston, Ontario K7L 4X3, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Sep 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 6, 2025
StartActual
Mar 31, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07009158
Lead sponsor
Dr. Yuliya Knyahnytska
Collaborators
Kingston Health Sciences Centre, Providence Care Hospital
Responsible party
Dr. Yuliya Knyahnytska (Qualified Investigator, Queen's University) — Sponsor-investigator
First posted
Jun 6, 2025
Start date
Mar 31, 2026
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Sep 15, 2026

Study contacts

Etienne J Bisson, PhD
Contact
etienne.bisson@kingstonhsc.ca
16135443400 ext. 23347

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion